Foster Jordan, Corporate Senior Vice President of the Endotoxin and Microbial Detection division, discusses the process of detecting, quantifying, and identifying microorganisms in products and facilities more rapidly, objectively, and efficiently than the traditional method of growing microorganisms in culture media.
Carl Craig, Corporate Vice President Global Bacterial Identification Services and EMD Product Distribution, discusses Charles River’s leadership position in the Microbiology QC testing market.
Foster Jordan, Corporate Senior Vice President of the Endotoxin and Microbial Detection division speaks with Outsourcing-Pharma.com on how bacterial testing is moving from the lab to the manufacturing floor.
In this interview with Contract Pharma, Foster Jordan, Corporate Senior Vice President of Endotoxin and Microbial Detection at Charles River, discusses drug safety testing, technologies and processes, contamination issues, and complexities and inefficiencies impacting the lab through to manufacturing.
Five toxicologic pathologists offer their perspectives on the benefits and challenges of forging a career in toxicology.
The devil is in the details when it comes to ensuring reliable, reproducible immunopotency assays in vaccine testing.
While the process of drug discovery remains constant, the groups driving the scientific innovation now include those typically associated with fund-raising, lobbying and patient advocacy. Along with biopharmaceutical companies, which have been at the helm of drug discovery for years, one finds an increasing number of not-for-profit disease foundations angling for a seat at the lab bench.
While challenges remain, PCR-based strategies for direct testing of quarantined rodents and for monitoring dust can replace, reduce or refine the use of sentinel mice in the infectious screening process, supporting the 3R philosophy while greatly improving the detection of rodent infectious agents to help keep animal colonies safe.
Live from the JP Morgan Healthcare Conference, James Foster, chairman and CEO at Charles River Laboratories spoke with Mad Money on CNBC. James Foster and Jim Cramer discuss the company’s strategic focus on helping accelerate drug discovery and development.
CHDI Foundation, Inc. has extended its ongoing collaboration with Charles River Laboratories for discovering novel drugs for Huntington's disease for an additional five years.